We are live on ! Find out more
ABI

Adamant Biomedical Investments Portfolio holdings

AUM $418M
This Fund
S&P 500
This Quarter Est. Return
+10.95%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$418M
AUM Growth
+$17.7M
Cap. Flow
-$20M
Cap. Flow %
-4.77%
Top 10 Hldgs %
32.81%
Holding
108
New
12
Increased
10
Reduced
35
Closed
7

Top Buys

Rank Stock Value
1
HSP
HOSPIRA INC
HSP
+$5.08M
2
WX
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
+$4.94M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.82M
4
MDVN
MEDIVATION, INC.
MDVN
+$4.68M
5
LGND icon
Ligand Pharmaceuticals
LGND
+$4.24M

Top Sells

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$4.8M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$4.11M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.02M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$3.9M
5
QGENF
QIAGEN NV
QGENF
+$3.53M

Sector Composition

Rank Sector Weight
1 Healthcare 87.28%
2 Financials 0.93%
3 Industrials 0.35%
4 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
76
DELISTED
Medicines Co
MDCO
$1.38M 0.33%
50,000
– –
SGEN
77
DELISTED
Seagen Inc. Common Stock
SGEN
$1.28M 0.31%
40,000
– –
ACHN
78
DELISTED
Achillion Pharmaceuticals
ACHN
$1.23M 0.29%
100,000
+20,000
+25% +$244K
NPSP
79
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$1.22M 0.29%
34,000
– –
RMD icon
80
ResMed
RMD
$30.7B
$1.12M 0.27%
20,000
-39,450
-66% -$2.06M
COV
81
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$1.02M 0.24%
10,000
-50,000
-83% -$4.8M
NBIX icon
82
Neurocrine Biosciences
NBIX
$16.6B
$1M 0.24%
45,000
– –
UTHR icon
83
United Therapeutics
UTHR
$23.1B
$906K 0.22%
7,000
-8,000
-53% -$1.03M
COR icon
84
Cencora
COR
$61.2B
$902K 0.22%
10,000
– –
MYGN icon
85
Myriad Genetics
MYGN
$312M
$817K 0.2%
24,000
– –
IMMU
86
DELISTED
Immunomedics Inc
IMMU
$720K 0.17%
150,000
– –
WCG
87
DELISTED
Wellcare Health Plans, Inc.
WCG
$656K 0.16%
8,000
– –
IPXL
88
DELISTED
Impax Laboratories, Inc.
IPXL
$634K 0.15%
20,000
– –
IQV icon
89
IQVIA
IQV
$39.3B
$589K 0.14%
+10,000
New +$571K
HALO icon
90
Halozyme
HALO
$12.2B
$579K 0.14%
60,000
– –
CLDX icon
91
Celldex Therapeutics
CLDX
$3.28B
$548K 0.13%
2,000
– –
INVA icon
92
Innoviva
INVA
$1.48B
$495K 0.12%
35,000
-65,000
-65% -$977K
AFFX
93
DELISTED
Affymetrix Inc
AFFX
$494K 0.12%
50,000
-50,000
-50% -$437K
EXEL icon
94
Exelixis
EXEL
$13.4B
$432K 0.1%
300,000
– –
INFI
95
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$287K 0.07%
17,000
– –
IMS
96
DELISTED
IMS HEALTH HLDGS INC COM STK (DE)
IMS
$256K 0.06%
+10,000
New +$252K
TBPH icon
97
Theravance Biopharma
TBPH
$877M
$171K 0.04%
11,428
– –
GERN icon
98
Geron
GERN
$949M
$146K 0.03%
45,000
– –
AST
99
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$6K ﹤0.01%
+1,875
New +$7.55K
BTX.WS
100
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$2K ﹤0.01%
+2,294
New +$2.49K
1 2 3
4
5

Similar funds

AGCJ
Alden Global Capital (Jersey) St. Helier, Jersey $415M AUM 31.95% 1-Year Est. Return
ACM
Alistair Capital Management Dallas, Texas $391M AUM 5.89% 1-Year Est. Return
RNS
Robert N. Shapiro $501M AUM 11.7% 1-Year Est. Return
NTP
Nine Ten Partners Evanston, Illinois $308M AUM
MMC
MDV Management Company Menlo Park, California $296M AUM
LOM
Loeb Offshore Management New York $547M AUM 50.11% 1-Year Est. Return
CAMI
Concord Asset Management (Illinois) Chicago, Illinois $288M AUM 11.06% 1-Year Est. Return
NES
New England Securities New York $285M AUM 7.18% 1-Year Est. Return

Adamant Biomedical Investments's Q4 2014 Portfolio in Review

As of Q4 2014, Adamant Biomedical Investments held 108 positions worth $418M, up 4.4% from $401M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Adamant Biomedical Investments withdrew a net $20M in Q4 2014, closing 7 positions and reducing 35 holdings. Its most notable exit was Insulet, an estimated $2.95M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier, followed by Financials and Industrials.

Against the trend, Adamant Biomedical Investments opened a new position in HOSPIRA INC worth $5.51M.

  • Adamant Biomedical Investments's largest Q4 2014 buy was HOSPIRA INC: 90,000 shares worth $5.51M.
  • Adamant Biomedical Investments added most to Acadia Pharmaceuticals in Q4 2014, an estimated $4.82M increase.
  • Adamant Biomedical Investments's biggest Q4 2014 reduction was COVIDIEN PLC COM SHS NEW (IRELAND), cutting an estimated $4.8M.
  • Adamant Biomedical Investments fully exited Insulet in Q4 2014, selling an estimated $2.95M.
  • Adamant Biomedical Investments's ten largest holdings make up 33% of its $418M portfolio in Q4 2014.
  • Adamant Biomedical Investments opened 12 new positions and closed 7 in Q4 2014.
  • Adamant Biomedical Investments's portfolio value rose 4.4% quarter-over-quarter to $418M.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.